



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

7 Dec 2020 (#53)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices

- [NOT-HG-21-016](#) Notice of Intent to Publish a Funding Opportunity Announcement for Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21). The purpose of the RFA is to refocus and emphasize NHGRI's investment in nucleic acid sequencing technology on novel technology innovation and early development

## Upcoming Deadlines

- [Harnessing Data Science for Health Discovery and Innovation in Africa \(DS-I Africa\)](#): Research Hubs AIDS application due date: 8 February 2021
- [Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries D43](#) 24 June 2021

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notices of Special Interest (NOSI)

- [NOT-HG-21-004](#) Notice of Special Interest (NOSI): High-throughput Molecular and Cellular Phenotyping. The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel methods to perform high-throughput molecular and cellular phenotyping in order to elucidate the functional consequences of DNA variation.

### 1. Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-21-014](#)

**Type:** U01

**Application Due Date:** June 8, 2021; November 17, 2021 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

**Budget:** NCI intends to commit \$2,250,000 in FY 2022 to fund 5-6 awards. Budgets are limited to \$300,000 Direct Costs (excluding consortium F&A) per year. The maximum project period is three years.

### 2. Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-21-015](#)

**Type:** U24

**Application Due Date:** June 08, 2021; November 17, 2021 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.

**Budget:** NCI intends to commit \$3,600,000 in FY 2022 to fund 4 awards. Budgets are limited to \$600,000 Direct Costs (excluding consortium F&A) per year. The maximum project period is five years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105